U.S. MARKETS FOR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY AND CORONARY STENTING PRODUCTS

269 Pages | 61 Exhibits | 2007 Analysis | Forecasts Through 2011 Product Family: Market Reports




OVERVIEW:
Percutaneous transluminal coronary angioplasty (PTCA) and coronary stenting represent the device-based, non-surgical treatments of choice for patients with advanced coronary heart disease that cannot be adequately managed with medical therapy. Sales of PTCA products and coronary stents/stent systems in the U.S. reached approximately $4.1 billion in 2006. In recent months, growth in this market has been negatively affected by a combination of factors including reports of the rare but life-threatening condition, late stent thrombosis, that has been associated with the use of drug-eluting coronary stents.

This comprehensive new report from Medtech Insight includes analyses of current and emerging products, technologies, markets, competitors, and opportunities in the U.S. markets for PTCA and coronary stenting products.

Covered topics in this report include bare-metal stents; coronary artery bypass grafting; coronary guiding catheters and guidewires; coronary stent coatings, configurations, and materials; coronary stenting complications, outcomes, and procedure volumes; drug-eluting stents; embolic protection devices; endothelial progenitor cell capture antibody and antisense technologies; facilitated angioplasty; healthcare statistics; inflation devices; introducers/sheaths; PTCA balloon catheters; PTCA procedure volumes; vascular access site closure devices; and technological developments in PTCA and coronary stenting.

TABLE OF CONTENTS:

EXECUTIVE SUMMARY

i.       Percutaneous Transluminal Coronary Angioplasty and Coronary Stenting, Procedure Volumes Forecast

ii.       Percutaneous Transluminal Coronary Angioplasty and Coronary Stenting Products, Combined Market Forecast

iii.     Percutaneous Transluminal Coronary Angioplasty Products Market

a.     Balloon Catheters

b.     Guiding Catheters

c.       Guidewires

d.     Introducers/Sheaths

e.     Inflation Devices

f.       Vascular Access Closure Devices

g.     Embolic Protection Devices

iv.     Coronary Stents and Stent Systems Market

a.     Bare-Metal Stents

b.     Drug-Eluting Stents

v.     Methodology

 

Exhibit ES-1:       Percutaneous Transluminal Coronary Angioplasty, Historic and Forecast Procedure Volumes, 1994-2011

Exhibit ES-2:       Coronary Stenting, Historic and Forecast Procedure Volumes, 1996-2011

Exhibit ES-3:       Percutaneous Transluminal Coronary Angioplasty and Coronary Stenting Products, Market Forecast, 2006-2011

Exhibit ES-4:       Percutaneous Transluminal Coronary Angioplasty Products, Combined Market Forecast, 2006-2011

Exhibit ES-5:       Percutaneous Transluminal Coronary Angioplasty Balloon Catheters, Market Forecast, 2006-2011

Exhibit ES-6:       Guiding Catheters for Coronary Interventions, Market Forecast, 2006-2011

Exhibit ES-7:       Guidewires for Coronary Interventions, Market Forecast, 2006-2011

Exhibit ES-8:       Introducers/Sheaths for Coronary Interventions, Market Forecast, 2006-2011

Exhibit ES-9:       Inflation Devices for Coronary Interventions, Market Forecast, 2006-2011

Exhibit ES-10:   Vascular Access Site Closure Devices, Market Forecast, 2006-2011

Exhibit ES-11:   Embolic Protection Devices for Interventional Cardiology Applications, Market Forecast, 2006-2011

Exhibit ES-12:   Coronary Stents, Combined Market Forecast, 2006-2011

Exhibit ES-13:   Bare-Metal Coronary Stents, Market Forecast, 2006-2011

Exhibit ES-14:   Drug-Eluting Coronary Stents, Market Forecast, 2006-2011

 

1. CORONARY HEART DISEASE OVERVIEW

1.1 Heart Anatomy and Physiology

1.2 Coronary Heart Disease

1.2.1 Atherosclerosis

1.2.2 Angina Pectoris

1.2.3 Myocardial Infarction

1.3 Coronary Heart Disease Management Options

1.3.1 Medical Management

1.3.1.1 Lifestyle Changes

1.3.1.1.1 Diet Modification

1.3.1.1.2 Smoking Cessation

1.3.1.2 Pharmaceuticals

1.3.1.2.1 Anticoagulants and Antiplatelet Drugs

1.3.1.2.2 Lipid-Lowering Drugs

1.3.1.2.3 Antihypertensive Drugs

1.3.1.2.4 Nitroglycerin Preparations

1.3.2 Surgical Intervention

1.3.2.1 Coronary Artery Bypass Graft Surgery

1.3.2.2 Transmyocardial Revascularization

1.3.3 Percutaneous Coronary Interventions

1.3.3.1 Percutaneous Transluminal Coronary Angioplasty

1.3.3.2 Coronary Stenting

 

Exhibit 1-1:           Cross-Section Diagram of the Normal Heart

Exhibit 1-2:           Statistics for Selected Heart Disease Risk Factors

Exhibit 1-3:           Standard Angina Pectoris Classification

Exhibit 1-4:           Angina Pectoris, Selected Statistics

Exhibit 1-5:           Myocardial Infarction, Selected Statistics

Exhibit 1-6:           2006, Percentage of Tobacco Smokers, by State and Gender

Exhibit 1-7:           2005, Percentage of Acute Myocardial Infarction Patients Prescribed Aspirin at Hospital Discharge, by State

Exhibit 1-8:           2005, Percentage of Acute Myocardial Infarction Patients Prescribed an Angiotensin-Converting Enzyme Inhibitor or an Angiotensin Receptor Blocker at Hospital Discharge, by State

Exhibit 1-9:           2005, Percentage of Acute Myocardial Infarction Patients Prescribed a Beta Blocker at Hospital Discharge, by State

Exhibit 1-10:       Coronary Artery Bypass Grafting, Historic Procedure Volumes, 1994-2004

Exhibit 1-11:       Percutaneous Coronary Interventions, Historic Procedure Volumes, 1994-2004

 

2. PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY PRODUCTS MARKET

2.1 Percutaneous Transluminal Coronary Angioplasty Technique

2.1.1 Approaches

2.1.2 Applications

2.1.3 Efficacy

2.1.4 Complications

2.1.5 Adjunctive Anti-Clotting Drug Therapies

2.1.5.1 Anti-Clotting Strategies for Percutaneous Coronary Interventions

2.1.5.2 Facilitated Angioplasty

2.1.6 Costs

2.1.7 Procedure Volumes

2.2 Percutaneous Transluminal Coronary Angioplasty Products

2.2.1 Balloon Catheters

2.2.1.1 Market Forecast

2.2.1.2 Competitive Analysis

2.2.2 Guiding Catheters

2.2.2.1 Market Forecast

2.2.2.2 Competitive Analysis

2.2.3 Guidewires

2.2.3.1 Market Forecast

2.2.3.2 Competitive Analysis

2.2.4 Introducers/Sheaths

2.2.4.1 Market Forecast

2.2.4.2 Competitive Analysis

2.2.5 Inflation Devices

2.2.5.1 Market Forecast

2.2.5.2 Competitive Analysis

2.2.6 Vascular Access Closure Devices

2.2.6.1 Market Forecast

2.2.6.2 Competitive Analysis

2.2.7 Embolic Protection Devices

2.2.7.1 Distal Filter Devices

2.2.7.2 Distal Balloon Occlusion Devices

2.2.7.3 Proximal Balloon Occlusion Devices

2.2.7.4 Market Analysis

2.2.7.5 Competitive Analysis

 

Exhibit 2-1:           Selected Hospital Outcomes Data for Percutaneous Transluminal Coronary Angioplasty Patients

Exhibit 2-2:           2004, Mean Hospital Charges for Percutaneous Transluminal Coronary Angioplasty Procedures

Exhibit 2-3:           Percutaneous Transluminal Coronary Angioplasty, Historic Procedure Volumes, 1994-2004

Exhibit 2-4:           Percutaneous Transluminal Coronary Angioplasty, Procedure Volumes Forecast, 2005-2011

Exhibit 2-5:           Percutaneous Transluminal Coronary Angioplasty Products, Combined Market Forecast, 2006-2011

Exhibit 2-6:           2007, Selected Percutaneous Transluminal Coronary Angioplasty Balloon Catheters

Exhibit 2-7:           Percutaneous Transluminal Coronary Angioplasty Balloon Catheters, Market Forecast, 2006-2011

Exhibit 2-8:           2006, Percutaneous Transluminal Coronary Angioplasty Balloon Catheters Market, Share by Supplier

Exhibit 2-9:           2007, Selected Guiding Catheters for Coronary Interventions

Exhibit 2-10:       Guiding Catheters for Coronary Interventions, Market Forecast, 2006-2011

Exhibit 2-11:       2006, Market for Guiding Catheters for Coronary Interventions, Share by Supplier

Exhibit 2-12:       2007, Selected Guidewires for Coronary Interventions

Exhibit 2-13:       Guidewires for Coronary Interventions, Market Forecast, 2006-2011

Exhibit 2-14:       2006, Market for Guidewires for Coronary Interventions, Share by Supplier

Exhibit 2-15:       2007, Selected Introducers/Sheaths for Coronary Interventions

Exhibit 2-16:       Introducers/Sheaths for Coronary Interventions, Market Forecast, 2006-2011

Exhibit 2-17:       2006, Market for Introducers/Sheaths for Coronary Interventions, Share by Supplier

Exhibit 2-18:       2007, Selected Inflation Devices for Coronary Interventions

Exhibit 2-19:       Inflation Devices for Coronary Interventions, Market Forecast, 2006-2011

Exhibit 2-20:       2006, Market for Inflation Devices for Coronary Interventions, Share by Supplier

Exhibit 2-21:       2007, Selected Vascular Access Site Closure Devices

Exhibit 2-22:       Vascular Access Site Closure Devices, Market Forecast, 2006-2011

Exhibit 2-23:       2006, Vascular Access Site Closure Devices Market, Share by Supplier

Exhibit 2-24:       2007, Selected Embolic Protection Systems for Interventional Cardiology Applications

Exhibit 2-25:       Embolic Protection Devices for Interventional Cardiology Applications, Market Forecast, 2006-2011

Exhibit 2-26:       2006, Market for Embolic Protection Devices for Interventional Cardiology Applications, Share by Supplier

 

3. CORONARY STENTS AND STENT SYSTEMS MARKET

3.1 Coronary Stent Designs

3.1.1 Stent Materials

3.1.1.1 Stainless Steel

3.1.1.2 Nitinol

3.1.1.3 Tantalum

3.1.1.4 Cobalt-Chromium Alloys

3.1.1.5 Bioabsorbable Materials

3.1.2 Stent Coatings/Surfaces

3.1.2.1 Inert

3.1.2.1.1 Carbon

3.1.2.1.2 Ionic Oxygen

3.1.2.1.3 Polymers

3.1.2.2 Drug-Eluting

3.1.2.2.1 Sirolimus-Eluting

3.1.2.2.2 Paclitaxel-Eluting

3.1.2.2.3 Everolimus-Eluting

3.1.2.2.4 Zotarolimus-Eluting

3.1.2.2.5 Tacrolimus-Eluting

3.1.2.2.6 Biolimus A9-Eluting

3.1.2.3 Biological Material-Carrying

3.1.2.3.1 Endothelial Progenitor Cell Capture Antibodies

3.1.2.3.2 Antisense Agents

3.1.3 Stent Configurations

3.1.3.1 Coil

3.1.3.2 Tubular

3.2 Coronary Stenting

3.2.1 Stent Delivery

3.2.2 Stent Deployment

3.2.3 Indications

3.2.4 Complications and Outcomes

3.2.5 Costs

3.2.6 Procedure Volumes

3.3 Coronary Stents/Stent Systems

3.3.1 Products

3.3.2 Product Pricing

3.3.3 Market Forecast

3.3.4 Competitive Analysis

 

Exhibit 3-1:           2004, Mean Hospital Charges for Coronary Stenting Procedures

Exhibit 3-2:           2006, Estimated Consumables Cost per Coronary Stenting Procedure

Exhibit 3-3:           Coronary Stenting, Historic Procedure Volumes, 1996-2004

Exhibit 3-4:           Coronary Stenting, Procedure Volumes Forecast, 2005-2011

Exhibit 3-5:           2007, Selected Coronary Stents

Exhibit 3-6:           Bare-Metal Coronary Stents, Market Forecast, 2006-2011

Exhibit 3-7:           Drug-Eluting Coronary Stents, Market Forecast, 2006-2011

Exhibit 3-8:           Coronary Stents, Combined Market Forecast, 2006-2011

Exhibit 3-9:           2006, Bare-Metal Coronary Stents Market, Share by Supplier

Exhibit 3-10:       2006, Drug-Eluting Coronary Stents Market, Share by Supplier

 

4. COMPANY PROFILES

4.1       Abbott Vascular/Abbott Laboratories

4.2       Arrow International, Inc./Teleflex, Inc.

4.3       B. Braun Melsungen AG

4.4       BIOTRONIK GmbH & Company KG

4.5       Boston Scientific Corporation

4.6       Cook Group, Inc.

4.7       Cordis/Johnson & Johnson

4.8       ev3, Inc.

4.9       InSitu Technologies, Inc.

4.10   Medtronic, Inc.

4.11   Merit Medical Systems, Inc.

4.12   OrbusNeich

4.13   St. Jude Medical, Inc.

4.14   Sorin Group SPA

4.15   Terumo Medical Corporation/Terumo Corporation

 

APPENDIX:   COMPANY LISTING



COMPANIES COVERED:

  1. Abbott Vascular/Abbott Laboratories
  2. Arrow International, Inc./Teleflex, Inc.
  3. B. Braun Melsungen AG
  4. BIOTRONIK GmbH & Company KG
  5. Boston Scientific Corporation
  6. Cook Group, Inc.
  7. Cordis/Johnson & Johnson
  8. ev3, Inc.
  9. InSitu Technologies, Inc.
  10. Medtronic, Inc.
  11. Merit Medical Systems, Inc.
  12. OrbusNeich
  13. St. Jude Medical, Inc.
  14. Sorin Group SPA
  15. Terumo Medical Corporation/Terumo Corporation
Contact Us

Need help finding medtech research? Let us help you!